Compound
calcium citrate
A colorless crystalline or white powdery organic, tricarboxylic acid occurring in plants, especially citrus fruits, and used as a flavoring agent, as an antioxidant in foods, and as a sequestrating agent. (McGraw-Hill Dictionary of Scientific and Technical Terms, 4th ed)
Structure
No three-dimensional record for this entry.
- Formula
- 2C6H5O7.3Ca
- Mass
- 498.432 g/mol
- Charge
- 0
- InChIKey
- FNAQSUUGMSOBHW-UHFFFAOYSA-H
- SMILES
- O=C([O-])CC(O)(CC(=O)[O-])C(=O)[O-].O=C([O-])CC(O)(CC(=O)[O-])C(=O)[O-].[Ca+2].[Ca+2].[Ca+2]
- Look it up
- ChEBIBy InChIKey
Identity from ChEBI. Not evidence.
What the reference databases state
Statements
1 statement
1 statement · 1 reference database · Subject: calcium citrate · Sources: ChEBI
- calcium citrate is converted to citric acidCompoundChEBI CHEBI:190513Inferred only
Registered, and not reported
- Source
- ClinicalTrials.gov
- Intervention
- calcium citrate
- Status
- Completed, terminated or suspended
- Results posted
- No
Trials without posted results
89 trials
89 registered trials without posted results · Overdue (FDAAA 801): 85
85 past the window4 within it, or no actual date
- NCT07255820completed2026-03-30a university or hospital
- NCT06742853completed2025-10-29industry
- NCT06650930completed2025-10-11a university or hospitalpast the reporting window
- NCT05365477completed2025-09-26a university or hospitalpast the reporting window
- NCT06983509completed2025-09-11industrypast the reporting window
- NCT05836402completed2025-08-04a university or hospitalpast the reporting window
- NCT07306611completed2025-06-18a university or hospitalpast the reporting window
- NCT06821698completed2025-05-20industrypast the reporting window
- NCT05814341completed2024-12-15a university or hospitalpast the reporting window
- NCT06132269completed2024-01-30industrypast the reporting window
- NCT05775822completed2023-12-20a university or hospitalpast the reporting window
- NCT06429306completed2023-11-24industrypast the reporting window
Show the remaining 77
- NCT06146712completed2023-10-02industrypast the reporting window
- NCT05592951completed2023-07-14a university or hospitalpast the reporting window
- NCT05974982completed2023-05-25a government bodypast the reporting window
- NCT04444765completed2022-12-31a university or hospitalpast the reporting window
- NCT05589051completed2022-10-28a university or hospitalpast the reporting window
- NCT05523115completed2022-10-01industrypast the reporting window
- NCT05280106completed2022-09-30a government bodypast the reporting window
- NCT04297839suspended— DUE TO CORONAVIRUS DISEASE, ACTIVITIES INTHE HOSPITAL ARE SUPRESSEDexpected 2022-07-31a university or hospital
- NCT05339542completed2022-07-01a university or hospitalpast the reporting window
- NCT04792424completed2022-05-30a university or hospitalpast the reporting window
- NCT05510791completed2022-05-10a university or hospitalpast the reporting window
- NCT02921893completed2022-04-21a university or hospitalpast the reporting window
- NCT04620252completed2022-03-31a university or hospitalpast the reporting window
- NCT04959110completed2021-12-31a university or hospitalpast the reporting window
- NCT03399539completed2021-12-20a university or hospitalpast the reporting window
- NCT04062812completed2021-10-01a university or hospitalpast the reporting window
- NCT03842657completed2021-09-13a university or hospitalpast the reporting window
- NCT04530175completed2021-07-07a university or hospitalpast the reporting window
- NCT06646328terminated— Enrollment slower than anticipated and interrupted by COVID-19 pandemic2021-04-30a university or hospitalpast the reporting window
- NCT04211272completed2021-04-19industrypast the reporting window
- NCT04764565completed2021-04-06a university or hospitalpast the reporting window
- NCT05149053completed2021-02-26a university or hospitalpast the reporting window
- NCT01217372completed2021-02-16a university or hospitalpast the reporting window
- NCT04865510completed2021-01-15a government bodypast the reporting window
- NCT04299633completed2020-08-02industrypast the reporting window
- NCT03425747completed2020-04-01a university or hospitalpast the reporting window
- NCT03863873completed2019-12-01a university or hospitalpast the reporting window
- NCT04040309completed2019-08-20a university or hospitalpast the reporting window
- NCT03380754completed2019-08-01a university or hospitalpast the reporting window
- NCT02669589completed2019-04-03a university or hospitalpast the reporting window
- NCT03452696completed2019-03-28a university or hospitalpast the reporting window
- NCT02469558completed2018-12-31a university or hospitalpast the reporting window
- NCT03256838completed2018-12-31industrypast the reporting window
- NCT02414386completed2018-12-04a university or hospitalpast the reporting window
- NCT01731340completed2018-11-14a university or hospitalpast the reporting window
- NCT02930161terminated— Low recruitment2018-10-10industrypast the reporting window
- NCT05023122completed2017-12-31a university or hospitalpast the reporting window
- NCT03232034completed2017-12-05a university or hospitalpast the reporting window
- NCT03910036completed2017-12-05a university or hospitalpast the reporting window
- NCT02868489completed2017-11-29a university or hospitalpast the reporting window
- NCT02492620completed2017-11a university or hospitalpast the reporting window
- NCT03080207completed2017-08-01a university or hospitalpast the reporting window
- NCT05750602completed2017-07industrypast the reporting window
- NCT02830789completed2017-05a university or hospitalpast the reporting window
- NCT02565602completed2016-09a university or hospitalpast the reporting window
- NCT02352181completed2016-08a university or hospitalpast the reporting window
- NCT04452734completed2016-05-14a university or hospitalpast the reporting window
- NCT02663960completed2016-05a university or hospitalpast the reporting window
- NCT00572741completed2016-04a university or hospitalpast the reporting window
- NCT02824601completed2016-04a university or hospitalpast the reporting window
- NCT01204164completed2016-03industrypast the reporting window
- NCT01022229completed2015-11a university or hospitalpast the reporting window
- NCT00968565completed2015-06a university or hospitalpast the reporting window
- NCT02281045completed2015-05a university or hospitalpast the reporting window
- NCT01817218completed2015-01a government bodypast the reporting window
- NCT01370200completed2014-12a university or hospitalpast the reporting window
- NCT01551368terminated— small number of patients got recruited2014-04a university or hospitalpast the reporting window
- NCT01532297completed2013-04industrypast the reporting window
- NCT01965990completed2013-02a university or hospitalpast the reporting window
- NCT04344821completed2012-05-03a university or hospitalpast the reporting window
- NCT01139398completed2011-11industrypast the reporting window
- NCT00472823completed2011-08a university or hospitalpast the reporting window
- NCT00662844completed2011-08a university or hospitalpast the reporting window
- NCT00354302completed2011-03a research networkpast the reporting window
- NCT00282126completed2011-01a university or hospitalpast the reporting window
- NCT01330940completed2010-07US federal agencypast the reporting window
- NCT00913796completed2010-03a university or hospitalpast the reporting window
- NCT00638300completed2009-12a university or hospitalpast the reporting window
- NCT00704990completed2009-12a university or hospitalpast the reporting window
- NCT00742820completed2008-11industrypast the reporting window
- NCT00073060completed2008-08-26NIHpast the reporting window
- NCT00718289completed2007-11a university or hospitalpast the reporting window
- NCT01329042completed2007-10industrypast the reporting window
- NCT01312194completed2007-05a university or hospitalpast the reporting window
- NCT03878667completed2005-12-31a university or hospitalpast the reporting window
- NCT00591708completed2005-08a university or hospitalpast the reporting window
- NCT00004361completedno completion dateNIH
Papers screened
74 papers
- Compound
- calcium citrate
- Screened
- 74
- Admitted
- 0
- Discarded
- 56
- Not read
- 18
Discarded: another reason, stated per paper22 papers
- PMID:19287339no claim extracted — cause not determined — DOSED: no compound given; observational measurement of endogenous urinary citrate and calcium in children, abstract2026-10-11
- PMID:8295783no claim extracted — cause not determined — DOSED: no compound given; observational study of endogenous citrate, calcium and acid-base in spinal cord injured patients, abstract2026-10-11
- PMID:38345765no claim extracted — cause not determined (one pass only) — measured: treatment adherence/compliance rate to an oral calcium supplement2026-09-29
- PMID:39203002no claim extracted — design_has_no_evidence_type2026-09-29
- NCT00145977design×1 — allocation NON_RANDOMIZED -- not randomised2026-09-24
- NCT00416715design×1 — allocation NA -- not randomised2026-09-24
- NCT00653068design×1 — allocation NON_RANDOMIZED -- not randomised2026-09-24
- NCT01275664design×1 — allocation NA -- not randomised2026-09-24
- NCT01385098design×1 — allocation NA -- not randomised2026-09-24
- NCT01864018design×1 — allocation NA -- not randomised2026-09-24
- NCT02119468design×1 — allocation NON_RANDOMIZED -- not randomised2026-09-24
- NCT02547662design×1 — allocation NA -- not randomised2026-09-24
and 10 more.
Discarded: the wrong intervention19 papers
- PMID:33672071no claim extracted — reagent_not_exposure2026-09-29
- NCT00025259intervention×1 — no declared intervention names calcium citrate2026-09-24
- NCT00336024intervention×1 — no declared intervention names calcium citrate2026-09-24
- NCT01013792intervention×1 — no declared intervention names calcium citrate2026-09-24
- NCT01191255intervention×1 — no declared intervention names calcium citrate2026-09-24
- NCT01266850intervention×1 — no declared intervention names calcium citrate2026-09-24
- NCT01317940intervention×1 — no declared intervention names calcium citrate2026-09-24
- NCT01415882intervention×1 — no declared intervention names calcium citrate2026-09-24
- NCT01754779intervention×1 — no declared intervention names calcium citrate2026-09-24
- NCT01803607intervention×1 — no declared intervention names calcium citrate2026-09-24
- NCT01920152intervention×1 — no declared intervention names calcium citrate2026-09-24
- NCT02029521intervention×1 — no declared intervention names calcium citrate2026-09-24
and 7 more.
Discarded: an endpoint this vocabulary does not hold10 papers
- PMID:1452953no claim extracted — no_outcome_node — measured: 24-hour urinary calcium excretion, 24-hour urine collection on constant metabolic diet | 24-hour urinary calcium excretion; urinary citrate; urinary saturation of stone-forming salts2026-10-11
- PMID:15086461no claim extracted — no_outcome_node — measured: inulin clearance (rat GFR); histologic glomerular and tubulointerstitial damage score; urinary protein excretion rate | inulin clearance (GFR) in rats; histologic glomerular/tubulointerstitial damage score; proteinuria2026-10-11
- PMID:22437685no claim extracted — no_outcome_node — measured: integrated loss of subsurface enamel hardness (deltaKHN), cross-sectional Knoop microhardness, bovine enamel in vitro | enamel demineralization, Knoop surface and cross-sectional microhardness2026-10-11
- PMID:22449524no claim extracted — no_outcome_node — measured: bone defect healing, radiographic and histological bone formation in rabbit femur defect | bone defect healing, radiographic and histological bone formation2026-10-11
- PMID:23318822no claim extracted — no_outcome_node — measured: alpha-SMA and E-cadherin expression as EMT markers in HK2 cells, immunocytochemistry/Western blot | EMT markers (alpha-smooth muscle actin, E-cadherin) by immunocytochemistry/Western blot in HK2 cells2026-10-11
- PMID:23969915no claim extracted — no_outcome_node — measured: enamel mineral gain (%SH, %deltaZ), Knoop microhardness, bovine enamel in vitro | enamel remineralization, percent surface hardness change and cross-sectional hardness mineral gain2026-10-11
- PMID:25434759claims extracted but the object named resolved to no node — recorded in candidate_nodes (ADR-0070)2026-10-11
- PMID:39938817no claim extracted — no_outcome_node — measured: osteogenesis in rat skull defect repair, imaging/histology of new bone formation | bone defect repair, osteogenic effect in SD rat skull defect2026-10-11
- PMID:41060681no claim extracted — no_outcome_node — measured: acidosis-induced cellular oxidative stress, flow cytometry, in vitro | cellular oxidative stress under acidosis in vitro; cell injury by flow cytometry2026-10-11
- PMID:8453325no claim extracted — no_outcome_node — measured: serum and 24-hour urinary aluminum concentration before versus during calcium citrate, metabolic diet | serum aluminum concentration; urinary aluminum excretion; bone aluminum content2026-10-11
Discarded: no extractable result5 papers
- NCT00321932declared_contrast×9 — no posted analysis compares a calcium citrate arm with a placebo/no-intervention arm and carries a p-value (Arm I (Standard of Care)=unmatched, Arm II (Treatment With Zometa)=unmatched)2026-09-24
- NCT00580047declared_contrast×2 — no posted analysis compares a calcium citrate arm with a placebo/no-intervention arm and carries a p-value (Intravenous Bisphosphonate Post Transplantation=unmatched, Oral Bisphosphonate Post Transplantation=unmatched, Placebo Group Post Transplantation=unmatched)2026-09-24
- NCT00729183declared_contrast×9, stratified×4, multiple_analyses×1 — no posted analysis compares a calcium citrate arm with a placebo/no-intervention arm and carries a p-value (Odanacatib 50 mg=EXPERIMENTAL+subject, Placebo=PLACEBO_COMPARATOR+subject)2026-09-24
- NCT01400516declared_contrast×3 — no posted analysis compares a calcium citrate arm with a placebo/no-intervention arm and carries a p-value (Control Arm=OTHER+subject, Teriparatide=EXPERIMENTAL+subject)2026-09-24
- NCT03994172declared_contrast×6 — no posted analysis compares a calcium citrate arm with a placebo/no-intervention arm and carries a p-value (Combination Therapy Arm: Teriparatide (TPTD) + the Calcimimetic Cinacalcet=EXPERIMENTAL+subject, Monotherapy Arm: Teriparatide (TPTD) + Placebo=PLACEBO_COMPARATOR+subject)2026-09-24
Not read yet18 papers
- PMID:93121962026-09-29
- PMID:249370252026-09-29
- PMID:113291142026-09-29
- PMID:153110082026-09-29
- PMID:217039422026-09-29
- PMID:222222992026-09-29
- PMID:22666792026-09-29
- PMID:258516352026-09-29
- PMID:102316072026-09-01
- PMID:182913082026-09-01
- PMID:20222212026-09-01
- PMID:214051462026-09-01
and 6 more.
Measured, not recorded
- Compound
- calcium citrate
- Endpoints measured
- 94 endpoints
- Recorded as a finding
- No
Show what was measured
fall in urinary phosphorus
decreases, n = 12
The fall in urinary phosphorus was equivalent at about 25% between Ca citrate phases
PMID:1452953 · one of two readings recorded this
rise in urinary Ca from control phase
increases, n = 12
The rise from the control phase in urinary Ca was slightly more prominent when Ca citrate was given with meals than without (68 and 62%, respectively)
PMID:1452953 · one of two readings recorded this
rise in urinary Ca from control phase
increases, n = 12
The rise from the control phase in urinary Ca was slightly more prominent when Ca citrate was given with meals than without (68 and 62%, respectively)
PMID:1452953 · one of two readings recorded this
serum iron
no effect, n = 12
There was a nonsignificant rise in serum iron during Ca citrate phases
PMID:1452953 · one of two readings recorded this
urinary ammonium
decreases, n = 12
The rise in urinary citrate and pH and the decline in urinary ammonium were more prominent when Ca citrate was given with meals; however, the changes were small or nonsignificant
PMID:1452953 · one of two readings recorded this
urinary citrate
increases, n = 12
The rise in urinary citrate and pH and the decline in urinary ammonium were more prominent when Ca citrate was given with meals; however, the changes were small or nonsignificant
PMID:1452953 · one of two readings recorded this
urinary pH
increases, n = 12
The rise in urinary citrate and pH and the decline in urinary ammonium were more prominent when Ca citrate was given with meals; however, the changes were small or nonsignificant
PMID:1452953 · one of two readings recorded this
urinary saturation of Ca oxalate, brushite or monosodium urate
no effect, n = 12
The urinary saturation of Ca oxalate, brushite or monosodium urate did not differ between the two Ca citrate phases
PMID:1452953 · one of two readings recorded this
glomerular cell transdifferentiation (alpha-smooth muscle actin, desmin)
decreases, p = 0.05
less glomerular cell transdifferentiation and higher plasma bicarbonate at 10 weeks (P < 0.05)
PMID:15086461 · one of two readings recorded this
glomerular cellular proliferation (PCNA-positive cells)
decreases, p = 0.05
The treated groups showed significantly less glomerular and tubulointerstitial cellular proliferation in the first week (P < 0.05)
PMID:15086461 · one of two readings recorded this
histologic glomerular damage score
decreases, p = 0.05
as well as diminished histologic glomerular and tubulointerstitial damage scores at 20 weeks (P < 0.05)
PMID:15086461 · one of two readings recorded this
histologic tubulointerstitial damage score
decreases, p = 0.05
as well as diminished histologic glomerular and tubulointerstitial damage scores at 20 weeks (P < 0.05)
PMID:15086461 · one of two readings recorded this
inulin clearance
increases, p = 0.05
Inulin clearances were higher (P < 0.05)
PMID:15086461 · one of two readings recorded this
plasma (arterial) bicarbonate concentration
increases, p = 0.05
less glomerular cell transdifferentiation and higher plasma bicarbonate at 10 weeks (P < 0.05)
PMID:15086461 · one of two readings recorded this
systolic blood pressure
no effect
arterial blood pressure was not significantly different in the NFX-CIT group
PMID:15086461 · one of two readings recorded this
tubulointerstitial cellular proliferation (PCNA-positive cells)
decreases, p = 0.05
The treated groups showed significantly less glomerular and tubulointerstitial cellular proliferation in the first week (P < 0.05)
PMID:15086461 · one of two readings recorded this
urine protein excretion rate
decreases, p = 0.05
urine protein excretion rates were lower (P < 0.05)
PMID:15086461 · one of two readings recorded this
5th percentile of random urine citrate/creatinine ratio
We found 5th percentile for random urine citrate/creatinine ratio in school-aged children to be 176 mg/g
PMID:19287339 · one of two readings recorded this
urine calcium/citrate ratio discrimination cutoff between control and stone formers (ROC)
found calcium/citrate ratio of 0.326 to provide good discrimination between control and stone formers
PMID:19287339 · one of two readings recorded this
urine calcium/citrate ratio
increases, p = 0.001
urine calcium/citrate ratio (mg/mg) increased from control 0.17 +/- 0.17 to 0.41 +/- 0.23 (p < 0.001) in hypercalciuric nonstone formers
PMID:19287339 · one of two readings recorded this
urine calcium/citrate ratio
increases, p = 0.001
and to 0.65 +/- 0.46 in stone formers (p < 0.001 compared with other groups)
PMID:19287339 · one of two readings recorded this
urine citrate/creatinine
increases, p = 0.01
Urine citrate/creatinine was highest in hypercalciuric nonstone formers 899 +/- 351 compared with controls 711 +/- 328 and stone formers 595 +/- 289 (p < 0.01 vs. both)
PMID:19287339 · one of two readings recorded this
baseline surface hardness (SH)
no effect, p = 0.05
No statistical differences were observed among the blocks for the SH, regardless of the treatments (p>0.05)
PMID:22437685 · one of two readings recorded this
correlation integrated loss of subsurface hardness versus fluoride in enamel
decreases, p = 0.001
there was a negative correlation between ∆KHN and fluoride (r=-0.909; p<0.001)
PMID:22437685 · one of two readings recorded this
correlation SH1 versus fluoride in enamel
increases, p = 0.001
A positive correlation was observed between SH1 and fluoride in enamel (r=0.885; p<0.001)
PMID:22437685 · one of two readings recorded this
correlation SH1 versus integrated loss of subsurface hardness
decreases, p = 0.001
There was a negative correlation between SH1 and ∆KHN (r=-0.933; p<0.001)
PMID:22437685 · one of two readings recorded this
fluoride in enamel
modulates, p = 0.05
it was different from the positive control (p<0.05)
PMID:22437685 · one of two readings recorded this
fluoride in enamel
no effect, p = 0.05
Although group 1,000 µg F/g presented similar results when compared to 1,100 µg F/g (p>0.05)
PMID:22437685 · one of two readings recorded this
fluoride in enamel
no effect, p = 0.05
No difference was observed between group 450 µg F/g and 550 µg F/g (p>0.05)
PMID:22437685 · one of two readings recorded this
integrated loss of subsurface hardness (dKHN)
no effect, p = 0.05
No difference was observed among groups 450, 1,000, 1,100 µg F/g and positive control (p>0.05)
PMID:22437685 · one of two readings recorded this
surface hardness after pH cycling (SH1)
increases, p = 0.05
All groups showed a significant decrease in SH1 after pH cycling; the experimental dentifrice with 1,000 µg F/g showed the highest value of hardness (p<0.05)
PMID:22437685 · one of two readings recorded this
surface hardness after pH cycling (SH1)
no effect, p = 0.05
There was no significant difference (p>0.05) among groups 450, 1,100 µg F/g and positive control
PMID:22437685 · one of two readings recorded this
bone formation in femur defects (radiological and histological)
no effect
No statistical difference was observed when these defects were larger than 2.0 mm at all healing periods except at the 4th week
PMID:22449524 · one of two readings recorded this
bone formation in femur defects (radiological and histological)
increases
It showed significant difference between the experimental group and the control group when these defects were less than or equal to 2.0 mm
PMID:22449524 · one of two readings recorded this
early bone defect healing
increases
Calcium citrate affects the early periods of bone defects healing mechanism in Japanese white rabbits positively, especially when the defect is not too large
PMID:22449524 · one of two readings recorded this
acidosis-induced EMT
decreases
Calcium citrate decreased acidosis induced EMT and improved cells performance, without reduction of TGF-β production
PMID:23318822 · one of two readings recorded this
cellular performance (change in intracellular calcium concentration, basal and after Angiotensin II)
increases
Calcium citrate decreased acidosis induced EMT and improved cells performance, without reduction of TGF-β production
PMID:23318822 · one of two readings recorded this
E-cadherin expression
decreases
At pH 7.0 HK2 cells significantly reduced E-cadherin and increased α-SMA expression (EMT)
PMID:23318822 · one of two readings recorded this
α-SMA expression
increases
At pH 7.0 HK2 cells significantly reduced E-cadherin and increased α-SMA expression (EMT)
PMID:23318822 · one of two readings recorded this
supernatant TGF-β1 level
increases
Supernatant TGF-β1 levels were higher than in control group
PMID:23318822 · one of two readings recorded this
TGF-β production
no effect
Calcium citrate decreased acidosis induced EMT and improved cells performance, without reduction of TGF-β production
PMID:23318822 · one of two readings recorded this
fluoride in enamel versus fluoride concentration in toothpaste
increases
A dose-response was observed between fluoride concentration in toothpastes and fluoride present in enamel, regardless of dilution
PMID:23969915 · one of two readings recorded this
mineral gain (%SH and %∆Z)
no effect, p = 0.05
The 450 Cacit/TMP toothpaste and the positive control showed similar results (p>0.05) when diluted in water
PMID:23969915 · one of two readings recorded this
mineral gain (%SH and %∆Z)
no effect, p = 0.05
except for the 450 µgF/g dentifrice with Cacit/TMP (p>0.05)
PMID:23969915 · one of two readings recorded this
mineral gain (%SH and %∆Z)
increases, p = 0.05
The mineral gain (%SH and %∆Z) was higher for toothpastes diluted in saliva (p<0.05)
PMID:23969915 · one of two readings recorded this
activities of superoxide dismutase, catalase and glutathione peroxidase
increases
Treatment of cells with calcium citrate (10-100μM) significantly reduced the generation of intracellular reactive oxygen species and increased the activities of the antioxidant enzymes superoxide dismutase, catalase, and glutathione peroxidase in LPS-stimulated macrophages
PMID:25434759 · one of two readings recorded this
expression of iNOS, COX-2 and NF-κB
decreases
The expression levels of iNOS, COX-2, and NF-κB were also suppressed by treatment with calcium citrate
PMID:25434759 · one of two readings recorded this
IL-6 and TNF-alpha production in LPS-stimulated RAW 264.7 macrophage culture, not circulating serum immunoassay
decreases
Not recorded as a finding: cell-culture cytokine production; outcome nodes interleukin-6 and tnf-alpha require circulating serum or plasma concentration
Calcium citrate was furthermore found to significantly inhibit the production of IL-1β, IL-6, and TNF-α in response to LPS-stimulation.
PMID:25434759 · one of two readings recorded this
intracellular reactive oxygen species
decreases
Treatment of cells with calcium citrate (10-100μM) significantly reduced the generation of intracellular reactive oxygen species
PMID:25434759 · one of two readings recorded this
nitric oxide production
decreases
Calcium citrate was further shown to inhibit NO production in LPS-stimulated RAW 264.7cells
PMID:25434759 · one of two readings recorded this
production of IL-1β, IL-6 and TNF-α
decreases
Calcium citrate was furthermore found to significantly inhibit the production of IL-1β, IL-6, and TNF-α in response to LPS-stimulation
PMID:25434759 · one of two readings recorded this
TNF-alpha production in LPS-stimulated RAW 264.7 cell culture, immunoassay not stated
decreases
Not recorded as a finding: tnf-alpha node is circulating serum or plasma concentration; this is cell-culture production, so no mapping
Calcium citrate was furthermore found to significantly inhibit the production of IL-1β, IL-6, and TNF-α in response to LPS-stimulation.
PMID:25434759 · one of two readings recorded this
nanoparticle size and percentage drug loading of triazine derivative 2a in calcium citrate nanoparticles
size 148 ± 23 nm; drug loading up to 16.3%
With the optimised conditions, "CaCit-2a NPs" were successfully synthesised with the size of 148 ± 23 nm and %drug loading of up to 16.3%.
PMID:33672071 · one of two readings recorded this
adverse reaction (AR) incidence attributed to calcium citrate supplementation
n = 231
A total of 9 subjects (3.9%) experienced at least one AR.
PMID:38345765 · one of two readings recorded this
adverse reaction (AR) occurrence attributed to calcium citrate supplementation
n = 231
A total of 9 subjects (3.9%) experienced at least one AR.
PMID:38345765 · one of two readings recorded this
systolic and diastolic blood pressure, change from baseline to follow-up visit
decreases, p = 0.0102, n = 65
In a subset of individuals where SBP was measured (N = 65), mean SBP was observed to decrease from 130.7 ± 16.9 mmHg to 127.9 ± 14.5 mmHg (p = 0.0102) from baseline to V2.
PMID:38345765 · one of two readings recorded this
systolic and diastolic blood pressure, mmHg (clinical vital-sign measurement)
decreases, p = 0.0102, n = 65
Not recorded as a finding: the result compares a group with itself, not with a control
In a subset of individuals where SBP was measured (N = 65), mean SBP was observed to decrease from 130.7 ± 16.9 mmHg to 127.9 ± 14.5 mmHg (p = 0.0102) from baseline to V2.
PMID:38345765 · one of two readings recorded this
treatment adherence, calculated from compliance and persistence
mean adherence 76.6 ± 29.5%, median 91.0%, n = 222
In this study, we observed an average adherence to oral calcium citrate supplementation of 76.6 ± 29.5%, with a median of 91.0%.
PMID:38345765 · one of two readings recorded this
hydroxyapatite (HAp) formation from calcium citrate powder alone, assessed by XRD, SEM, ICP-OES and FTIR after simulated body fluid immersion
no effect, smaller quantity (0.0094 g) fully converted to HAp; larger quantity (0.047 g) retained its original crystalline phase with no significant conversion
This result indicated that a smaller quantity of CC (0.0094 g) underwent a full transformation into HAp upon SBF immersion, whereas a larger quantity (0.047 g) retained its original crystalline phase, exhibiting no significant conversion.
PMID:39203002 · one of two readings recorded this
hydroxyapatite (HAp) formation from calcium citrate powder and OCP/calcium-citrate/gelatine composites immersed in simulated body fluid, assessed by XRD, SEM, FTIR and ICP-OES
decreases, 0.0094 g CC underwent full conversion to HAp; 0.047 g CC retained its original crystalline phase with no significant conversion
Not recorded as a finding: a design this vocabulary does not classify
This result indicated that a smaller quantity of CC (0.0094 g) underwent a full transformation into HAp upon SBF immersion, whereas a larger quantity (0.047 g) retained its original crystalline phase, exhibiting no significant conversion.
PMID:39203002 · one of two readings recorded this
hydroxyapatite (HAp) formation from calcium citrate powder and octacalcium phosphate/calcium citrate/gelatine composites immersed in simulated body fluid, assessed by XRD, SEM, FTIR and ICP-OES
decreases
Not recorded as a finding: a design this vocabulary does not classify
This suggested that the inclusion of CC in the samples prepared in 24-well plates inhibited HAp formation in an SBF.
PMID:39203002 · one of two readings recorded this
hydroxyapatite (HAp) formation from CC powder in simulated body fluid, by XRD/SEM/ICP-OES/FTIR
decreases, 0.0094 g CC fully converted to HAp; 0.047 g CC showed no significant conversion, retaining its original crystalline phase
This result indicated that a smaller quantity of CC (0.0094 g) underwent a full transformation into HAp upon SBF immersion, whereas a larger quantity (0.047 g) retained its original crystalline phase, exhibiting no significant conversion.
PMID:39203002 · one of two readings recorded this
hydroxyapatite (HAp) formation from octacalcium phosphate/calcium citrate/gelatine composites, by XRD after simulated body fluid immersion
decreases
This suggested that the inclusion of CC in the samples prepared in 24-well plates inhibited HAp formation in an SBF.
PMID:39203002 · one of two readings recorded this
hydroxyapatite (HAp) formation in OCP/CC/gelatine composites prepared in 24-well plates, by XRD
decreases, only the 70% OCP/30% gelatine sample (no CC) formed HAp; the 35% OCP/35% CC/30% gelatine and 70% CC/30% gelatine composites did not form HAp
The samples that contained CC, namely the 35% OCP/35% CC/30% Gel and 70% CC/30% Gel composites, did not form HAp.
PMID:39203002 · one of two readings recorded this
cell activities (MC3T3-E1)
decreases
while cell activities were inhibited by excessive Ca2+
PMID:39938817 · one of two readings recorded this
cell adhesion, proliferation and differentiation (MC3T3-E1)
increases
The rapid and efficient release of Ca2+ from the scaffolds could significantly promote cell adhesion, proliferation, and differentiation
PMID:39938817 · one of two readings recorded this
cross-linking degree and efficiency of chitosan/gelatin scaffolds
increases
The results confirmed that citric acid significantly improved the cross-linking degree and efficiency of the chitosan/gelatin scaffolds
PMID:39938817 · one of two readings recorded this
cross-linking degree, water absorption and resistance to enzymatic degradation
decreases
But the addition of Ca2+ reduced the cross-linking degree, water absorption, and resistance to enzymatic degradation of the scaffolds
PMID:39938817 · one of two readings recorded this
mechanical strength of scaffold
increases
the supersaturated calcium citrate formed inside the scaffold increased its mechanical strength
PMID:39938817 · one of two readings recorded this
osteogenic effect in skull defect repair
increases
the chitosan/gelatin/supersaturated calcium citrate scaffolds with 25 mM Ca2+ added had a stronger osteogenic effect compared to the chitosan/gelatin scaffolds
PMID:39938817 · one of two readings recorded this
acidosis-induced cell injury (flow cytometry)
decreases
Flow cytometry further demonstrated superior protection by CN and CCN against acidosis-induced cell injury
PMID:41060681 · one of two readings recorded this
acidosis-induced oxidative stress
decreases
In particular, acidosis-induced oxidative stress was significantly attenuated by CN and CCN, outperforming sodium citrate
PMID:41060681 · one of two readings recorded this
cellular uptake and cytotoxicity
no effect
Both nanoparticles showed efficient cellular uptake in normal and acidic environments with minimal cytotoxicity at 1 mg ml-1
PMID:41060681 · one of two readings recorded this
intracellular and extracellular bicarbonate levels
no effect
Although CN had only a slight alkalinizing effect in vitro, intracellular and extracellular bicarbonate levels did not differ significantly between treatment groups after 24 hours
PMID:41060681 · one of two readings recorded this
particle size
CN and CCN exhibited particle sizes of 50 to 70 nm and 60 to 80 nm, with zeta potentials of -16.1 and -13.0 mV, and citrate content of 31% and 25%, respectively
PMID:41060681 · one of two readings recorded this
zeta potential
CN and CCN exhibited particle sizes of 50 to 70 nm and 60 to 80 nm, with zeta potentials of -16.1 and -13.0 mV, and citrate content of 31% and 25%, respectively
PMID:41060681 · one of two readings recorded this
filtered load of citrate
decreases
Patients with normal glomerular filtration had lower filtered load of citrate than the controls
PMID:8295783 · one of two readings recorded this
fractional renal tubular reabsorption of citrate
no effect
Fractional renal tubular reabsorption of citrate did not differ between patients with normal renal function and control subjects
PMID:8295783 · one of two readings recorded this
plasma bicarbonate
increases
Plasma pH and bicarbonate were within the normal range but higher in the patients than in the control subjects
PMID:8295783 · one of two readings recorded this
plasma calcium
increases
Plasma calcium was within the normal range but higher in patients within 1 year of onset of the cord lesion than it was later or than was found in control subjects
PMID:8295783 · one of two readings recorded this
plasma citrate
decreases
Urinary and plasma citrate were lower in the patients than in the controls
PMID:8295783 · one of two readings recorded this
plasma pH
increases
Plasma pH and bicarbonate were within the normal range but higher in the patients than in the control subjects
PMID:8295783 · one of two readings recorded this
urinary ammonium
decreases
When patients with urea-splitting infection were omitted the patients had a higher urinary pH and a lower urinary ammonium than the controls
PMID:8295783 · one of two readings recorded this
urinary citrate association with urinary potassium and creatinine clearance
unclear
Urinary citrate was related to urinary potassium and creatinine clearance
PMID:8295783 · one of two readings recorded this
urinary citrate
decreases
Urinary and plasma citrate were lower in the patients than in the controls
PMID:8295783 · one of two readings recorded this
urinary pH
increases
When patients with urea-splitting infection were omitted the patients had a higher urinary pH and a lower urinary ammonium than the controls
PMID:8295783 · one of two readings recorded this
mineralization defect on bone histomorphometry
no effect
In them, histomorphometric examination did not show any evidence of mineralization defect
PMID:8453325 · one of two readings recorded this
serum aluminum
serum and urinary aluminum were normal before treatment at 489 +/- 293 SD nmol/l (13.2 +/- 7.9 micrograms/l) and 767 +/- 497 nmol/day (20.7 +/- 13.4 micrograms/day), respectively
PMID:8453325 · one of two readings recorded this
serum aluminum
no effect
Similarly, no significant change in serum and urinary aluminum was detected in normal women during calcium citrate administration (271 +/- 59 vs 293 +/- 85 nmol/l and 515 +/- 138 vs 615 +/- 170 nmol/day, respectively)
PMID:8453325 · one of two readings recorded this
serum aluminum
no effect
They remained within normal limits and did not change significantly during calcium citrate treatment (400 +/- 148 nmol/l and 600 +/- 441 nmol/day, respectively)
PMID:8453325 · one of two readings recorded this
skeletal bone aluminum content
no effect, p = 0.727, n = 14
skeletal bone aluminum content did not change significantly in 14 osteoporotic patients (endogenous creatinine clearance of 68.5 ml/min) treated for 24 months with calcium citrate, 10 mmol calcium twice/day separately from meals (29.3 +/- 13.9 ng/mg ash bone to 27.9 +/0- 10.4, P = 0.727)
PMID:8453325 · one of two readings recorded this
urinary aluminum
serum and urinary aluminum were normal before treatment at 489 +/- 293 SD nmol/l (13.2 +/- 7.9 micrograms/l) and 767 +/- 497 nmol/day (20.7 +/- 13.4 micrograms/day), respectively
PMID:8453325 · one of two readings recorded this
urinary aluminum
no effect
Similarly, no significant change in serum and urinary aluminum was detected in normal women during calcium citrate administration (271 +/- 59 vs 293 +/- 85 nmol/l and 515 +/- 138 vs 615 +/- 170 nmol/day, respectively)
PMID:8453325 · one of two readings recorded this
urinary aluminum
no effect
They remained within normal limits and did not change significantly during calcium citrate treatment (400 +/- 148 nmol/l and 600 +/- 441 nmol/day, respectively)
PMID:8453325 · one of two readings recorded this
Other names
14 names
Resolves to: calcium citrate
- Also called
- 2-hydroxy-1,2,3-propanetricarboxylic acid calcium salt (2:3)calcium 2-hydroxy-1,2,3-propanetricarboxylate (3:2)calcium citrate tribasiccalcium citrate, tribasiccitric acid calcium salt (2:3)tribasic calcium citratetricalcium bis(2-hydroxypropane-1,2,3-tricarboxylic acid)tricalcium bis(citric acid)tricalcium citratetricalcium dicitrate
- Systematic name
- calcium 2-hydroxypropane-1,2,3-tricarboxylate (3:2)calcium 2-hydroxypropane-1,2,3-tricarboxylate (3/2)
- Sold as
- AcicontralCalcitrate